Petros Pharmaceuticals, a NASDAQ-listed company (NASDAQ:PTPI), announced significant advancements to its AI platform on May 6, 2025, aimed at facilitating the transition of prescription drugs to over-the-counter (OTC) status. This move aligns with the company's broader goal of increasing consumer access to medications and reducing drug prices, as prompted by a recent Executive Order from President Trump. The enhancements, developed in collaboration with a leading Big Data provider, are designed to improve processing speed, enhance fraud detection, and create a more user-friendly experience for both patients and pharmaceutical partners. Enhancements to the AI Platform Fady Boctor, Petros' President and Chief Commercial Officer, highlighted the importance of these upgrades, stating that each step builds upon the robust foundation of the company's technology. Key enhancements include AI-driven identity verification and big data integrations, which are crucial for ensuring safe and appropriate access to OTC medications. Boctor emphasized the company's commitment to continuous innovation, driven by the growing demand for OTC switch efficiency and supported by recent FDA guidance on Additional Conditions for Nonprescription Use (ACNU). About Petros Pharmaceuticals Petros Pharmaceuticals is at the forefront of the $38 billion self-care market, aiming to become a leading innovator by expanding access to key prescription drugs through OTC pathways. The company is developing a proprietary Software as a Service (SaaS) platform designed to assist pharmaceutical companies in meeting FDA standards for Rx-to-OTC transitions. This platform integrates Petros' Software as a Medical Device (SaMD) solution, which utilizes advanced AI and big data to enhance label comprehension, self-selection, and actual use trials—critical steps in the FDA's OTC switch process. The Pathway from Rx to OTC The process of switching a prescription drug to OTC involves several stages, beginning with the creation of a Drug Facts Label (DFL) that must be easily understood by consumers. Next, data must prove that consumers can make informed decisions based on the DFL and their medical histories. Finally, consumers must demonstrate proper usage of the product through Label Comprehension Studies (LCS), Self-Selection Studies (SSS), and Actual Use Trials (AUT). The FDA's introduction of ACNU criteria is particularly significant, as it allows for innovative computerized tools and other methods to support the switch process. Petros' technology platform is tailored to help companies navigate these requirements efficiently and effectively. Research and Development To date, Petros has completed eight critical studies (Formative Human Factors Studies in 2023 and 2024, Application Comprehension Studies in 2024, and a Two Arm All Comers Self Selection Study in 2024). These studies provide valuable data on the platform's effectiveness and user experience, reinforcing the company's claim that its technology can significantly aid in the FDA's OTC switch pathway. The integration of these findings with the latest big data technologies is expected to result in a commercially viable and reliable solution. Market Impact and Industry Insights The advancements in Petros' AI platform have garnered attention from industry insiders, who see the potential for this technology to accelerate the Rx-to-OTC switch process. By streamlining the regulatory pathway and enhancing consumer safety, Petros is poised to attract more pharmaceutical partners looking to extend the life cycle and accessibility of their products. Industry experts believe that the company's commitment to technology and compliance with FDA guidelines positions it strongly in the competitive self-care market. Company Profile Petros Pharmaceuticals, Inc. is a forward-thinking company dedicated to transforming the healthcare landscape by making prescription drugs more accessible as OTC treatments. With a focus on innovation and a deep understanding of regulatory requirements, Petros aims to leverage its SaaS and SaMD platforms to create safer, more affordable, and user-friendly therapeutic options. The company's ongoing collaboration with leading Big Data providers underscores its dedication to delivering cutting-edge solutions that benefit both patients and pharmaceutical companies. In conclusion, Petros Pharmaceuticals' latest enhancements to its AI platform mark a significant step in the company's mission to facilitate Rx-to-OTC switches. By aligning with FDA guidance and utilizing advanced technologies, Petros is set to play a pivotal role in the expanding self-care market, potentially revolutionizing how consumers access and manage their healthcare.